ICOS CORP|4Jan 30, 5:22 PM ET

GOODKIN DAVID A 4

4 · ICOS CORP · Filed Jan 30, 2007

Form 4

Period: 2007-01-29

VP, Devel. & Chief Med Off.

Transactions

Disposition to Issuer
Stock Option (right to buy)
2007-01-29$4.27/sh−62,300$266,021→ 0 total
Exercise: $29.73From: 2002-12-10Exp: 2012-12-10→ Common Stock (62,300 underlying)
Disposition to Issuer
Common Stock
2007-01-29$34.00/sh−1,000$34,000→ 0 total
Disposition to Issuer
Stock Option (right to buy)
2007-01-29$6.50/sh−100,000$650,000→ 0 total
Exercise: $27.50From: 2002-08-14Exp: 2012-08-14→ Common Stock (100,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
2007-01-29$8.62/sh−62,000$534,440→ 0 total
Exercise: $25.38From: 2005-01-27Exp: 2015-01-27→ Common Stock (62,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
2007-01-29$11.14/sh−25,000$278,500→ 0 total
Exercise: $22.86From: 2005-05-04Exp: 2015-05-03→ Common Stock (25,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
2007-01-29$9.11/sh−55,000$501,050→ 0 total
Exercise: $24.89From: 2006-01-24Exp: 2016-01-23→ Common Stock (55,000 underlying)
Disposition to Issuer
Common Stock
2007-01-29$34.00/sh−89,447$3,041,198→ 0 total

Footnotes (4)

[F1]Disposed of pursuant to the Merger Agreement under which Eli Lilly and Company ("Eli Lilly") acquired the Issuer ("Merger") and which provides for the cancellation of shares of common stock of the Issuer in exchange for $34.00 per share (the "Merger Consideration). Includes 68,100 shares of unvested restricted stock.
[F2]The options vested monthly in 1/48th increments over four years (48 months) commencing on the grant date indicated.
[F3]All options were cancelled pursuant to the Merger Agreement in exchange for cash consideration equal to the Merger Consideration less the exercise price per share.
[F4]Disposed of pursuant to the Merger Agreement which provides for the cancellation of shares of common stock of the Issuer in exchange for the Merger Consideration.

Documents

1 file